Predicting tumour response to chemoradiotherapy in oesophageal cancer by early interim 18F-FDG PET: where do we stand and where should we go?
Oesophageal cancer is a disease with a dismal prognosis and high mortality. There were an estimated 482,000 new cases and 407,000 patients died of the disease worldwide in 2008 . Concurrent chemotherapy and radiotherapy is now considered the neoadjuvant treatment of choice in patients with operable oesophageal cancer, as has been demonstrated by the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial . However, not all patients benefit from this treatment. In the CROSS trial, as much as 39 % of patients had no histopathological tumour regression (tumour regression defined as <10 % viable tumour cells in the resected specimen). Yet, toxicity due to chemotherapy occurs in 11–90 % and there is also a risk of radiation-induced complications [2, 3]. In patients who respond insufficiently, inefficient chemoradiotherapy should be discontinued, and surgery should not be delayed. On the other hand, patients who respond favourably may benefit from additional pr ...
- Ferlay, J, Shin, HR, Bray, F, Forman, D, Mathers, C, Parkin, DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: pp. 2893-2917 CrossRef
- Hagen, P, Hulshof, MC, Lanschot, JJ, Steyerberg, EW, Berge Henegouwen, MI, Wijnhoven, BP (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366: pp. 2074-2084 CrossRef
- Malthaner, RA, Collin, S, Fenlon, D (2006) Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 3: pp. CD001556
- Barber, TW, Duong, CP, Leong, T, Bressel, M, Drummond, EG, Hicks, RJ (2012) 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 53: pp. 864-871 CrossRef
- Weber, WA, Ott, K, Becker, K, Dittler, HJ, Helmberger, H, Avril, NE (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: pp. 3058-3065
- Ott, K, Weber, WA, Lordick, F, Becker, K, Busch, R, Herrmann, K (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24: pp. 4692-4698 CrossRef
- Wieder, HA, Brücher, BL, Zimmermann, F, Becker, K, Lordick, F, Beer, A (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: pp. 900-908 CrossRef
- Malik, V, Lucey, JA, Duffy, GJ, Wilson, L, McNamara, L, Keogan, M (2010) Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 51: pp. 1863-1869 CrossRef
- Heijl, M, Omloo, JM, Berge Henegouwen, MI, Hoekstra, OS, Boellaard, R, Bossuyt, PM (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253: pp. 56-63 CrossRef
- Cuenca X, Hennequin C, Hindié E, Rivera E, Vercellino L, Baruch-Hennequin V, et al. Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging 2013. doi:10.1007/s00259-012-2325-3.
- Shankar, LK, Hoffman, JM, Bacharach, S, Graham, MM, Karp, J, Lammertsma, AA (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47: pp. 1059-1066
- Boellaard, R, Oyen, WJ, Hoekstra, CJ, Hoekstra, OS, Visser, EP, Willemsen, AT (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35: pp. 2320-2333 CrossRef
- Predicting tumour response to chemoradiotherapy in oesophageal cancer by early interim 18F-FDG PET: where do we stand and where should we go?
European Journal of Nuclear Medicine and Molecular Imaging
Volume 40, Issue 4 , pp 475-476
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors